This test is minimally invasive, can be performed at any time point during disease course, and has, therefore, the potential to be inserted in algorithms for complementing IHC in assessing tumour PD-L1 status for a more efficient clinical management of OC patients in the era of precision medicine. Here, CD274 is linked to neoplasm.